Here are the 10-K annual reports from QHSLab, Inc (USAQ) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow USAQ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full USAQ filings page.
QHSLab, Inc. (USAQ) reports a small 2025 profit while warning that its ability to continue as a going concern is uncertain. The digital health and allergy-diagnostics company earned net income of $457,417 in 2025, helped by a one-time $666,000 gain from extinguishing debt, after a $259,239 loss in 2024.
Revenue rose to $2,691,741 in 2025 from $2,131,926 in 2024, driven by its QHSLab SaaS platform and AllergiEnd allergy products sold to independent primary care practices. The business still relies on external funding, taking $362,168 of loans and raising $499,998 of equity in 2025, and had $201,788 of notes and loans outstanding at year-end.
The company flags material weaknesses in internal controls due to limited staff and discloses significant regulatory, data-privacy and reimbursement risks tied to operating in heavily regulated healthcare and handling protected health information. As of March 30, 2026, QHSLab had 12 employees and 15,032,788 common shares outstanding; non‑affiliate holders owned 7,438,363 shares valued at $1,562,056 as of June 30, 2025.